Sander C.J. Verfaillie

Sander C.J. Verfaillie
Amsterdam University Medical Center | VUmc

PhD

About

120
Publications
14,125
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
2,113
Citations
Introduction
I am a postdoctoral researcher at the department of Medical Psychology Amsterdam UMC (Netherlands), and neuropsychologis/ health care psychologist at inGeest dept. of Anxiety, and dept. of personality disorders. I have obtained a PhD at the Amsterdam Alzheimercenter, focusing on the earliest changes related to Alzheimer's disease using PET and MRI techniques. I am currently conducting neuroimaging and neuropsychological research in the field of Alzheimer's and Long COVID-19

Publications

Publications (120)
Article
Full-text available
Purpose The role of cerebral blood flow (CBF) in the early stages of Alzheimer’s disease is complex and largely unknown. We investigated cross-sectional and longitudinal associations between CBF, amyloid burden, and cognition, in cognitively normal individuals with subjective cognitive decline (SCD). Methods We included 187 cognitively normal indi...
Article
Importance: Preventive trials of anti-amyloid agents might preferably recruit persons showing earliest biologically relevant β-amyloid (Aβ) binding on positron emission tomography (PET). Objective: To investigate the timing at which Aβ-PET binding starts showing associations with other markers of Alzheimer disease. Design, setting, and particip...
Article
Importance: National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD). Objective: To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-te...
Preprint
A significant number of COVID-19 patients develop 'long COVID', a condition defined by long-lasting debilitating, often neurological, symptoms. The pathophysiology of long COVID is unknown. Here we present in-vivo evidence of widespread neuroinflammation in long COVID, using a quantitative assessment, [ ¹⁸ F]DPA-714 PET, in two long COVID patients....
Article
Full-text available
Purpose Early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD) differ in neuropathological burden and type of cognitive deficits. Assessing tau pathology and relative cerebral blood flow (rCBF) measured with [¹⁸F]flortaucipir PET in relation to cognition may help explain these differences between EOAD and LOAD. Methods Se...
Article
Full-text available
Background and objectives: Multiple biomarkers have been suggested to measure neurodegeneration (N) in the AT(N) framework, leading to inconsistencies between studies. We investigated the association of 5 N biomarkers with clinical progression and cognitive decline in individuals with subjective cognitive decline (SCD). Methods: We included indi...
Article
Full-text available
[¹¹C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [¹¹C]UCB-J PET may serve as an in vivo marker of synaptic integrity. The main objective of this study was to evaluate the quantitative accuracy and the 28-day test–retest repeatability (TRT) of various parametric quantitative methods for dynamic [¹¹C]U...
Article
Different biomarkers have been suggested to measure neurodegeneration (N) in the ATN classification. We aimed to compare N biomarkers measured with different modalities and assess their association with clinical progression. We included 401 individuals with subjective cognitive decline (SCD, 61±9y, 42%F, MMSE28±2, follow‐up 3±3y). We used the follo...
Preprint
Full-text available
Purpose. Early-onset Alzheimer′ s disease (EOAD) and late-onset Alzheimer′ s disease (LOAD) differ in neuropathological burden and type of cognitive deficits. Assessing tau pathology and relative cerebral blood flow (rCBF) measured with [18F]flortaucipir PET in relation to cognition may help explain these differences between EOAD and LOAD. Methods....
Article
Full-text available
Objective To assess the [ ¹⁸ F]flortaucipir binding distribution across MAPT mutations in presymptomatic and symptomatic carriers. Methods We compared regional [ ¹⁸ F]flortaucipir binding potential(BP ND ) derived from a 130-minute dynamic [ ¹⁸ F]flortaucipir PET scan, in nine (pre)symptomatic MAPT mutation carriers(4 with P301L[1 symptomatic], 2...
Article
Full-text available
Purpose: Visual reading of 18F-florbetapir positron emission tomography (PET) scans is used in the diagnostic process of patients with cognitive disorders for assessment of amyloid-ß (Aß) depositions. However, this can be time-consuming, and difficult in case of borderline amyloid pathology. Computer-aided pattern recognition can be helpful in thi...
Article
Full-text available
Purpose: To determine thresholds for amyloid beta pathology and evaluate associations with longitudinal memory performance with the aim to identify a grey zone of early amyloid beta accumulation and investigate its clinical relevance. Methods: We included 162 cognitively normal participants with subjective cognitive decline from the SCIENCe coho...
Article
Full-text available
Background The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, we aimed to investigate spatial associations between regional tau pathology ([¹⁸F]flortaucipir PET), synaptic density (synaptic ve...
Article
Full-text available
Purpose The simplified reference tissue model (SRTM) is commonly applied for the quantification of brain positron emission tomography (PET) studies, particularly because it avoids arterial cannulation. SRTM requires a validated reference region which is obtained by baseline-blocking or displacement studies. Once a reference region is validated, the...
Article
Full-text available
PurposeWe aimed to investigate associations between tau pathology and relative cerebral blood flow (rCBF), and their relationship with cognition in Alzheimer’s disease (AD), by using a single dynamic [18F]flortaucipir positron emission tomography (PET) scan.Methods Seventy-one subjects with AD (66 ± 8 years, mini-mental state examination (MMSE) 23...
Conference Paper
Early‐onset Alzheimer’s disease (AD) dementia is characterized by a heterogeneous cognitive profile consisting of language and visuo‐spatial impairment. Spatial patterns of tau pathology measured with [18F]flortaucipir may help to explain the heterogeneity within early‐onset AD. Seventy‐one patients with Alzheimer’s disease dementia patients (n=28...
Article
Limited information is available on the genetic and environmental contributions to early AD pathology. Within a sample of cognitively unimpaired genetically identical older twins we aimed to assess 1) effects of amyloid‐ß pathology on [18F]flortaucipir (tau) binding and 2) spatial similarities in tau patterns within twin pairs. To date, ten twin pa...
Article
We aimed to compare different thresholds for amyloid‐beta pathology and their associations with memory decline, and to investigate the clinical significance of ‘grey zone’ amyloid‐beta burden in cognitively normal individuals. We included 162 cognitively normal participants with subjective cognitive decline (SCD) from the SCIENCe cohort (64±8yr, 38...
Article
Dementia with Lewy Bodies (DLB) is characterized by the presence of neuronal inclusions containing alpha‐synuclein proteins, and often co‐occurs with Alzheimer’s disease (AD) pathology. We aimed to determine the pattern of tau pathology and relative cerebral blood flow (rCBF) in DLB, compared to AD and controls, and their association with cognitive...
Conference Paper
The mechanisms contributing to synaptic loss in Alzheimer’s disease (AD) are poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, we therefore investigated associations between tau ([18F]flortaucipir PET), synaptic density (synaptic vesicle 2A [11C]UC...
Article
Full-text available
Purpose Alpha-synuclein often co-occurs with Alzheimer’s disease (AD) pathology in Dementia with Lewy Bodies (DLB). From a dynamic [¹⁸F]flortaucipir PET scan we derived measures of both tau binding and relative cerebral blood flow (rCBF). We tested whether regional tau binding or rCBF differed between DLB patients and AD patients and controls and e...
Article
Full-text available
PurposeIn vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [18F]flortaucipir positron emission tomography (PET). Our aim was to assess associations between CSF p-tau with [18F]flortaucipir PET and the associations of both tau biomarkers with cognition and atrophy.Methods We incl...
Article
Full-text available
The authors regret to inform readers that the following error was detected in the original article. The values for entorhinal, limbic and neortical SUVr were switched between SCD Aβ + and Aβ- in Table 1 and have now been corrected. Unnecessary symbols in Table 2 have been removed.
Article
Full-text available
[11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was to determine the 28-day test-retest repeatability (TRT) of quantitative [ 11 C]UCB-J brain positron emission tomog-raphy (PET) imaging in Alzheimer's disease (AD) patients and healthy controls (HCs). Nine HCs and eight AD pa...
Article
Full-text available
Background Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta (1-42/1-40) , glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) to identify ce...
Article
Full-text available
Objective To investigate the relationship between the ATN classification system (amyloid, tau, neurodegeneration) and risk of dementia and cognitive decline in individuals with subjective cognitive decline (SCD). Methods We classified 693 participants with SCD (60 ± 9 years, 41% women, Mini-Mental State Examination score 28 ± 2) from the Amsterdam...
Article
Full-text available
Accumulation of amyloid beta (Aβ) is one of the pathological hallmarks of Alzheimer’s disease (AD), which can be visualized using [ ¹⁸ F]florbetapir positron emission tomography (PET). The aim of this study was to evaluate various parametric methods and to assess their test-retest (TRT) reliability. Two 90 min dynamic [ ¹⁸ F]florbetapir PET scans,...
Article
Full-text available
Plasma biomarkers are promising prognostic tools in individuals with subjective cognitive decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta (Aβ)42/Aβ40 and total Tau (tTau) with rate of cognitive decline, in comparison to relationships of baseline cerebrospinal fluid (CSF) Aβ42, tTau, and phosphorylated tau181...
Article
Full-text available
Background: Off-target [18F]flortaucipir (tau) PET binding in the choroid plexus causes spill-in into the nearby hippocampus, which may influence the correlation between [18F]flortaucipir binding and measures of cognition. Previously, we showed that partial volume correction (combination of Van Cittert iterative deconvolution and HYPR denoising; P...
Article
Full-text available
The aim of this study was to investigate the test–retest (TRT) repeatability of various parametric quantification methods for [ ¹⁸ F]Flortaucipir positron emission tomography (PET). We included eight subjects with dementia or mild cognitive impairment due to Alzheimer’s disease and six cognitively normal subjects. All underwent two 130-min dynamic...
Poster
Full-text available
[11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A) present in neuronal presynaptic terminals. PET imaging with this radioligand should enable quantification of brain synaptic density by region and could serve as a research tool in clinical trials. The main objective of this study is to determine the test-retest...
Article
Full-text available
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the spatial distribution of neurofibrillary tangle pathology in post-mortem tissue, Braak staging has been used. The aim of this study was to examine in vivo associations between tau pathology, quantified with [18F]flortaucipir PET in regions correspondi...
Article
Full-text available
As nutrition is one of the modifiable risk factors for cognitive decline, we studied the relationship between dietary quality and clinical characteristics in cognitively normal individuals with subjective cognitive decline (SCD). We included 165 SCD subjects (age: 64 ± 8 years; 45% female) from the SCIENCe project, a prospective memory clinic based...
Article
Full-text available
Self-perceived word-finding difficulties are common in aging individuals as well as in Alzheimer's Disease (AD). Language deficits are difficult to objectify with neuropsychological assessments. We therefore aimed to investigate whether amyloid, an early AD pathological hallmark, is associated with speech-derived semantic complexity. We included 63...
Article
Full-text available
Background Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particular relevant for individuals who present at a memory clinic,...
Article
Full-text available
We examined the relationships between amyloid-β PET and concurrent and longitudinal cognitive performance in 107 cognitively normal individuals with subjective cognitive decline (age: 64 ± 8 years, 44% female, Mini-Mental State Examination score 29 ± 1). All underwent 90-minute dynamic [ ¹⁸ F]florbetapir PET scanning and longitudinal neuropsycholog...
Article
Full-text available
Objective: Subjective cognitive decline (SCD) is associated with an increased risk of Alzheimer’s Disease (AD). Early disease processes, such as amyloid-β aggregation measured with quantitative PET, may help to explain the phenotype of SCD. The aim of this study was to investigate whether quantitative amyloid-β load is associated with both self- an...
Article
Full-text available
Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer’s disease (AD) and non-AD dementia and (2) determinants of progression to dementia. Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dement...
Article
Full-text available
Introduction Individuals with subjective cognitive decline (SCD) are at increased risk for clinical progression. We studied how combining different diagnostic tests can help to identify individuals who are likely to show clinical progression. Methods We included 674 patients with SCD (46% female, 64 ± 9 years, Mini–Mental State Examination 28 ± 2)...
Article
Full-text available
Introduction: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD). The consistency of this finding across SCD studies has not been investigated. Methods: We studied gray matter volume differences between SCD subjects with and without cerebrospi...
Thesis
Subjective cognitive decline could be one of the earliest signs of Alzheimer’s disease, and portends risk of progression to dementia. Subjective cognitive decline can be caused by a myriad of factors, and neuroimaging biomarkers could help to identify those individuals at increased risk of Alzheimer’s disease. In this thesis, well-established and n...
Article
Full-text available
Objective We investigated the association of plasma amyloid beta (Abeta)40, Abeta42 and total tau (tTau) with the presence of Alzheimer's pathological changes in cognitively normal individuals with subjective cognitive decline (SCD). Methods We included 248 subjects with SCD (61±9yrs, 42%F, 28±2 MMSE) from the SCIENCe project and Amsterdam Dementi...
Article
Full-text available
Background: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria. Methods: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, includi...
Article
Full-text available
BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to crosssectionally describe participant characteristics, and to evaluate the SCD-plus criteria. METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including c...
Poster
Full-text available
We presented a project on the relation between nutrition and clinical characteristics of individuals with subjective cognitive decline.